AIM ImmunoTech Flags Going Concern, Cites Positive Phase 2 Pancreatic Cancer Data
AIM ImmunoTech’s auditor issued a going concern emphasis of matter on its 2025 consolidated financial statements, noting no amendments to the filings. Management cites positive Phase 2 data for Ampligen combined with Imfinzi in metastatic pancreatic cancer and expects a DURIPANC update in June 2026 to support fundraising.
1. Annual Filing Audit Emphasis
The Company’s audited consolidated financial statements for fiscal year 2025 included an emphasis of matter regarding the Company’s ability to continue as a going concern, as required by NYSE American rules, with no amendments to the original filings.
2. Phase 2 Clinical Progress
AIM reported positive developments in its Phase 2 DURIPANC trial evaluating Ampligen combined with Imfinzi for metastatic pancreatic cancer patients post-FOLFIRINOX, underlining promising efficacy signals.
3. Next Milestones and Fundraising Confidence
Management expressed confidence in securing additional financing based on the DURIPANC trial’s momentum and plans to provide the next clinical update in June 2026.